Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels

被引:26
作者
Guillaumet-Adkins, Amy [1 ]
Richter, Julia [2 ]
Odero, Maria D. [3 ]
Sandoval, Juan [4 ]
Agirre, Xabi [5 ,6 ,7 ]
Catala, Albert [8 ]
Esteller, Manel [4 ,9 ,10 ]
Prosper, Felipe [5 ,6 ,7 ]
Jose Calasanz, Maria [3 ]
Buno, Ismael [11 ]
Kwon, Mi [11 ]
Court, Franck [1 ]
Siebert, Reiner [2 ]
Monk, David [1 ]
机构
[1] Hosp Duran & Reynals, Inst Invest Biomed Bellvitge, Canc Epigenet & Biol Program, Imprinting & Canc Grp, Lhospitalet De Llobregat 08907, Spain
[2] Univ Kiel, Inst Human Genet, Kiel, Germany
[3] Univ Navarra, Dept Genet, E-31080 Pamplona, Spain
[4] Hosp Duran & Reynals, Inst Invest Biomed Bellvitge, Canc Epigenet & Biol Program, Canc Epigenet Grp, Barcelona 08907, Spain
[5] Univ Navarra, Div Canc, E-31080 Pamplona, Spain
[6] Univ Navarra, Area Cell Therapy, E-31080 Pamplona, Spain
[7] Univ Navarra, Hematol Serv, E-31080 Pamplona, Spain
[8] Hosp St Joan de Deu, Serv Heamatol, Barcelona, Spain
[9] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain
[10] ICREA, Barcelona, Catalonia, Spain
[11] Hosp Gen Univ Gregorio Maranon, Dept Hematol, Madrid, Spain
关键词
WT1; Methylation; Epigenetics; Leukemia; Imprinting; WILMS-TUMOR GENE; WT1; GENE; CHROMATIN PATTERN; MUTATIONS; METHYLATION; CANCER; OVEREXPRESSION; DIAGNOSIS; PREDICTS; CELLS;
D O I
10.1186/1756-8722-7-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Wilms tumor 1 (WT1) is over-expressed in numerous cancers with respect to normal cells, and has either a tumor suppressor or oncogenic role depending on cellular context. This gene is associated with numerous alternatively spliced transcripts, which initiate from two different unique first exons within the WT1 and the alternative (A) WT1 promoter intervals. Within the hematological system, WT1 expression is restricted to CD34+/ CD38- cells and is undetectable after differentiation. Detectable expression of this gene is an excellent marker for minimal residual disease in acute myeloid leukemia (AML), but the underlying epigenetic alterations are unknown. Methods: To determine the changes in the underlying epigenetic landscape responsible for this expression, we characterized expression, DNA methylation and histone modification profiles in 28 hematological cancer cell lines and confirmed the methylation signature in 356 cytogenetically well-characterized primary hematological malignancies. Results: Despite high expression of WT1 and AWT1 transcripts in AML-derived cell lines, we observe robust hypermethylation of the AWT1 promoter and an epigenetic switch from a permissive to repressive chromatin structure between normal cells and AML cell lines. Subsequent methylation analysis in our primary leukemia and lymphoma cohort revealed that the epigenetic signature identified in cell lines is specific to myeloid-lineage malignancies, irrespective of underlying mutational status or translocation. In addition to being a highly specific marker for AML diagnosis (positive predictive value 100%; sensitivity 86.1%; negative predictive value 89.4%), we show that AWT1 hypermethylation also discriminates patients that relapse from those achieving complete remission after hematopoietic stem cell transplantation, with similar efficiency to WT1 expression profiling. Conclusions: We describe a methylation signature of the AWT1 promoter CpG island that is a promising marker for classifying myeloid-derived leukemias. In addition AWT1 hypermethylation is ideally suited to monitor the recurrence of disease during remission in patients undergoing allogeneic stem cell transfer.
引用
收藏
页数:11
相关论文
共 33 条
[1]   DNA Methylation Profiles and Their Relationship with Cytogenetic Status in Adult Acute Myeloid Leukemia [J].
Alvarez, Sara ;
Suela, Javier ;
Valencia, Ana ;
Fernandez, Agustin ;
Wunderlich, Mark ;
Agirre, Xabier ;
Prosper, Felipe ;
Ignacio Martin-Subero, Jose ;
Maiques, Alba ;
Acquadro, Francesco ;
Rodriguez Perales, Sandra ;
Jose Calasanz, Maria ;
Roman-Gomez, Jose ;
Siebert, Reiner ;
Mulloy, James C. ;
Cervera, Jose ;
Angel Sanz, Miguel ;
Esteller, Manel ;
Cigudosa, Juan C. .
PLOS ONE, 2010, 5 (08)
[2]   Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia [J].
Andersson, Charlotta ;
Li, Xingru ;
Lorenz, Fryderyk ;
Golovleva, Irina ;
Wahlin, Anders ;
Li, Aihong .
DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (04) :225-233
[3]  
Baird PN, 1997, EXP HEMATOL, V25, P312
[4]   High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome [J].
Bergmann, L ;
Miething, C ;
Maurer, U ;
Brieger, J ;
Karakas, T ;
Weidmann, E ;
Hoelzer, D .
BLOOD, 1997, 90 (03) :1217-1225
[5]  
Carapeti M, 1997, EUR J HAEMATOL, V58, P346
[6]   Aberrant CpG-island methylation has non-random and tumour-type-specific patterns [J].
Costello, JF ;
Frühwald, MC ;
Smiraglia, DJ ;
Rush, LJ ;
Robertson, GP ;
Gao, X ;
Wright, FA ;
Feramisco, JD ;
Peltomäki, P ;
Lang, JC ;
Schuller, DE ;
Yu, L ;
Bloomfield, CD ;
Caligiuri, MA ;
Yates, A ;
Nishikawa, R ;
Huang, HJS ;
Petrelli, NJ ;
Zhang, XL ;
O'Dorisio, MS ;
Held, WA ;
Cavenee, WK ;
Plass, C .
NATURE GENETICS, 2000, 24 (02) :132-138
[7]   Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer [J].
Dallosso, Anthony R. ;
Hancock, Anne L. ;
Malik, Sally ;
Salpekar, Ashreena ;
King-Underwood, Linda ;
Pritchard-Jones, Kathy ;
Peters, Jo ;
Moorwood, Kim ;
Ward, Andrew ;
Malik, Karim T. A. ;
Brown, Keith W. .
RNA, 2007, 13 (12) :2287-2299
[8]   Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours [J].
Dallosso, AR ;
Hancock, AL ;
Brown, KW ;
Williams, AC ;
Jackson, S ;
Malik, K .
HUMAN MOLECULAR GENETICS, 2004, 13 (04) :405-415
[9]   Mutation in TET2 in Myeloid Cancers [J].
Delhommeau, Francois ;
Dupont, Sabrina ;
Della Valle, Veronique ;
James, Chloe ;
Trannoy, Severine ;
Masse, Aline ;
Kosmider, Olivier ;
Le Couedic, Jean-Pierre ;
Robert, Fabienne ;
Alberdi, Antonio ;
Lecluse, Yann ;
Plo, Isabelle ;
Dreyfus, Francois J. ;
Marzac, Christophe ;
Casadevall, Nicole ;
Lacombe, Catherine ;
Romana, Serge P. ;
Dessen, Philippe ;
Soulier, Jean ;
Viguie, Franck ;
Fontenay, Michaela ;
Vainchenker, William ;
Bernard, Olivier A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22) :2289-2301
[10]   Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation [J].
Figueroa, Maria E. ;
Abdel-Wahab, Omar ;
Lu, Chao ;
Ward, Patrick S. ;
Patel, Jay ;
Shih, Alan ;
Li, Yushan ;
Bhagwat, Neha ;
Vasanthakumar, Aparna ;
Fernandez, Hugo F. ;
Tallman, Martin S. ;
Sun, Zhuoxin ;
Wolniak, Kristy ;
Peeters, Justine K. ;
Liu, Wei ;
Choe, Sung E. ;
Fantin, Valeria R. ;
Paietta, Elisabeth ;
Lowenberg, Bob ;
Licht, Jonathan D. ;
Godley, Lucy A. ;
Delwel, Ruud ;
Valk, Peter J. M. ;
Thompson, Craig B. ;
Levine, Ross L. ;
Melnick, An .
CANCER CELL, 2010, 18 (06) :553-567